4DMedical

Executive Summary

4DMedical is an Australian med-tech company pioneering contrast-free functional lung imaging through its proprietary X-ray Velocimetry (XV) and CT-VQ technologies. By extracting regional ventilation and perfusion metrics from standard X-ray or CT scans, the company enables quantitative assessment of respiratory diseases such as COPD, asthma, interstitial lung disease, and post-transplant lung function. Founded in 2020 and headquartered in Perth, 4DMedical operates as a platform-stage private company with 50–200 employees, targeting a significant unmet need in pulmonary diagnostics. Its software-based approach offers a non-invasive, radiation-efficient alternative to traditional nuclear medicine techniques, potentially reducing patient burden and healthcare costs while providing actionable data for clinicians. The company's technology has been validated in multiple clinical studies, positioning it for adoption in both hospital and outpatient settings. 4DMedical's market opportunity is substantial, given the global prevalence of chronic respiratory diseases and the growing demand for objective, imaging-based biomarkers. The company is strategically positioned to capture value through equipment sales, per-study software fees, and potential partnerships with imaging OEMs and pharmaceutical companies. Near-term growth drivers include expanding its installed base in Australia and seeking regulatory clearance in key markets such as the United States and Europe. As a private entity, 4DMedical may also attract venture capital or strategic investment to accelerate commercialization and clinical evidence generation. With a differentiated product and a clear value proposition, the company is well-placed to disrupt the pulmonary imaging landscape, though execution risks remain around regulatory timelines and market penetration.

Upcoming Catalysts (preview)

• Q2 2026FDA 510(k) clearance for XV technology in a new clinical indication (e.g., interstitial lung disease)65% success
• Q3 2026Strategic partnership with a major hospital network or imaging OEM for deployment50% success
• Q4 2026Publication of Phase 2 clinical results demonstrating XV utility in post-COVID lung function assessment70% success